Deferasirox
Overview
Deferasirox belongs to iron chelators family. FDA approved it in November 2005. Deferasirox is the first drug approved in US for oral administration in the treatment of iron overload for anemia for the patients receiving blood transfusions. Iron chelators facilitate the removal of iron by making a bound with iron.
Categories
- 4 Antidotes and other substances used in poisonings
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Deferasirox's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 20 to 30 mg/kg | 25 (25) | 24 hourly | | |
Paedriatic Dosage (20kg)
|
| No data regarding the Paedriatic dosage details of Deferasirox is available. |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Deferasirox is available. |
High Risk Groups
Back to top
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Deferasirox
Back to top
Previous Drug Generic - Next Drug Generic